Moleculin Biotech Inc
MBRX
Company Profile
Business description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Contact
5300 Memorial Drive
Suite 950
HoustonTX77007
USAT: +1 713 300-5160
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.90 | 78.90 | -0.87% |
| CAC 40 | 8,238.17 | 23.99 | -0.29% |
| DAX 40 | 24,491.06 | 111.98 | -0.46% |
| Dow JONES (US) | 48,908.72 | 592.58 | -1.20% |
| FTSE 100 | 10,309.22 | 93.12 | -0.90% |
| HKSE | 26,456.53 | 428.71 | -1.59% |
| NASDAQ | 22,540.59 | 363.99 | -1.59% |
| Nikkei 225 | 53,984.74 | 166.70 | 0.31% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,798.40 | 84.32 | -1.23% |
| S&P/ASX 200 | 8,734.30 | 71.20 | -0.81% |
| SSE Composite Index | 4,073.75 | 2.16 | -0.05% |